This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Childhood B-acute lymphoblastic leukemia: a genetic update
Experimental Hematology & Oncology Open Access 13 June 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Willis TG, Dyer MJ . The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 2000; 96: 808–822.
Akasaka T, Balasas T, Russell LJ, Sugimoto KJ, Majid A, Walewska R et al. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2007; 109: 3451–3461.
Russell LJ, Akasaka T, Majid A, Sugimoto KJ, Loraine KE, Nagel I et al. t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2008; 111: 387–391.
Chapiro E, Russell L, Radford-Weiss I, Bastard C, Lessard M, Struski S, et al., the Groupe Francophone de Cytogenetique H. Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia. Blood 2006; 108: 3560–3563.
Harrison CJ, Martineau M, Secker-Walker LM . The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute lymphoblastic leukaemia: a valuable resource for patient management. Br J Haematol 2001; 113: 3–10.
Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW . Erythropoietin biology in cancer. Clin Cancer Res 2006; 12: 332–339.
Malinge S, Ben-Abdelali R, Settegrana C, Radford-Weiss I, Debre M, Beldjord K et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007; 109: 2202–2204.
Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci 2005; 102: 18962–18967.
Funakoshi-Tago M, Pelletier S, Moritake H, Parganas E, Ihle JN . Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol Cell Biol 2008; 28: 1792–1801.
Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 2008; 111: 3751–3759.
Ganmore I, Bercovich D, Scott LM, Green AR, Cazzaniga G, Biondi A et al. Collaboration between activating mutations in JAK2 and trisomy 21 in the acute lymphoblastic leukemias of down syndrome (DS). Blood 2007; 110: LB6.
Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF . Fetal anemia and apoptosis of red cell progenitors in Stat5a−/−5b−/− mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999; 98: 181–191.
Ward AC, Touw I, Yoshimura A . The Jak–Stat pathway in normal and perturbed hematopoiesis. Blood 2000; 95: 19–29.
Fine BM, Stanulla M, Schrappe M, Ho M, Viehmann S, Harbott J et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood 2004; 103: 1043–1049.
Inthal A, G K, Beck D, Joas R, Kauer MO, Orel GFL, Mann G et al. Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia. Clin Cancer Res 2008 (in press).
Acknowledgements
We thank all members of the UK Cancer Cytogenetics Group for providing cytogenetic data and the Clinical Trial Service Unit (CTSU, University of Oxford, UK) for providing trial data. This study could not have been performed without the dedication of the United Kingdom Children's Cancer and Leukaemia Group, Leukaemia and Lymphoma Division and Adult Leukemia Working Party, and their members who designed and coordinated the clinical trials through which these patients were identified and on which they were treated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Russell, L., De Castro, D., Griffiths, M. et al. A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin. Leukemia 23, 614–617 (2009). https://doi.org/10.1038/leu.2008.250
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.250
This article is cited by
-
Development of acute lymphoblastic leukemia with IgH-EPOR in a patient with secondary erythrocytosis
International Journal of Hematology (2016)
-
The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia
Leukemia (2015)
-
Childhood B-acute lymphoblastic leukemia: a genetic update
Experimental Hematology & Oncology (2014)
-
B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease
Modern Pathology (2014)